In the era of precision medicine, it is important to characterize melanoma tumors through molecular subtypes and to identify targeted therapies that are best suited for these subtypes—BRAF, RAS, NF1, and triple wild-type (Figure 1) [34]. The gene discussed is BRAF; the disease is melanoma.